Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Strata Critical Medical (SRTA) Research & Development (2020 - 2025)

Strata Critical Medical (SRTA) has disclosed Research & Development for 6 consecutive years, with $453000.0 as the latest value for Q3 2025.

  • Quarterly Research & Development rose 8.63% to $453000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $4.3 million through Sep 2025, up 42.25% year-over-year, with the annual reading at $3.2 million for FY2024, 31.19% down from the prior year.
  • Research & Development for Q3 2025 was $453000.0 at Strata Critical Medical, down from $915000.0 in the prior quarter.
  • The five-year high for Research & Development was $2.2 million in Q4 2024, with the low at $289000.0 in Q1 2021.
  • Average Research & Development over 5 years is $985315.8, with a median of $915000.0 recorded in 2025.
  • The sharpest move saw Research & Development soared 396.47% in 2021, then plummeted 61.25% in 2024.
  • Over 5 years, Research & Development stood at $702000.0 in 2021, then soared by 131.05% to $1.6 million in 2022, then plummeted by 39.09% to $988000.0 in 2023, then soared by 117.91% to $2.2 million in 2024, then plummeted by 78.96% to $453000.0 in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $453000.0, $915000.0, and $812000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.